Accelerating Next-Generation Medicines from Bench to Patients
Expert, customized translational science and biomarker strategy for biopharmaceutical innovators, focusing on complex diseases and modalities.
Expert Advisory Services
Translational & Biomarker Strategy
Translational gap analysis, biomarker deployment, and assay validation pathways from preclinical models to clinical proof-of-concept.
Pipeline & Portfolio Derisking
Hands-on guidance for complex cross-functional asset teams.
Preclinical & Clinical Development Advisory
Multi-year preclinical roadmapping aligning target validation, patient stratification, and indication expansion.
Bridging Preclinical Discovery & Clinical Proof-of-Concept
Bespoke translational science, biomarker architecture, and pipeline de-risking for advanced therapeutics.
Early asset progression requires rigorous validation and clear translational rationale. Niraamay Translational Partners delivers high-impact advisory services designed to solve complex preclinical bottlenecks, optimize disease modeling, and construct comprehensive biomarker strategies. By integrating multi-omic profiling, advanced ex-vivo systems, and clinical insight, we ensure your pipeline is engineered for measurable clinical success.
Target & Pathway Validation: Robust preclinical roadmapping to confirm mechanism of action.
Assay & Biomarker Deployment: High-resolution cellular and molecular readout strategies.
Strategic Asset De-risking: Objective portfolio assessment from discovery through Phase I proof-of-concept.
Translational & Biomarker Strategy: Flow cytometry panel design, transcriptomic/proteomic profiling, and clinical biomarker/strategy deployment.
Preclinical Modeling & Target Validation: Strategies utilizing human precision-cut tissue slices (PCTS), 3D organoids, humanized/genetically modified mouse models, and high-resolution imaging.
Advanced Modality Derisking: Engineering and delivery optimization for CAR-T, TCR, RLT, AAV vectors, siRNA, ASO, or circRNA.
Disease Area Deep-Dive: Specific mechanistic evaluations in immunology, renal, fibrotic, or respiratory indications.
General Pipeline & Portfolio Assessment: Broad strategic roadmapping for emerging biotechs.
Committed to Measurable Impact
The practice integrates rigorous analysis with industry expertise to deliver comprehensive strategies tailored to each client's operational realities.